Valeant Pharmaceuticals (NYSE:VRX) appoints Arthur Shannon as SVP, head of Investor Relations and Communications effective today. He joins the firm from Perrigo where he was VP of Global Corporate Affairs and European Investor Relations.
Scott Hirsch, SVP, Business Strategy and Communications will now devote his full efforts on developing and executing the company's five-year strategic plan as SVP, Chief Business Strategy Officer.
Now read: Valeant: Just Short It »
Subscribe for full text news in your inbox